Literature DB >> 34367971

Effects of Inflammation on the Immune Microenvironment in Gastric Cancer.

Weidan Zhao1, Mingqing Liu1, Mingyue Zhang1, Yachen Wang1, Yingli Zhang1, Shiji Wang2, Nan Zhang1.   

Abstract

BACKGROUND: Chronic inflammation and immune cell dysfunction in the tumor microenvironment are key factors in the development and progression of gastric tumors. However, inflammation-related genes associated with gastric cancer prognosis and their relationship with the expression of immune genes are not fully understood.
METHOD: In this study, we established an inflammatory response model score called "Riskscore", based on differentially expressed genes in gastric cancer. We used Survival and Survminer packages in R to analyze patient survival and prognosis in risk groups. The survival curve was plotted using the Kaplan-Meier method, and the log-rank test was used to assess statistical significance, and we performed the ROC analysis using the R language package to analyze the 1-, 3-, and 5-year survival of patients in the GEO and TCGA databases. Single-factor and multi-factor prognostic analyses were carried out for age, sex, T, N, M, and risk score. Pathway enrichment analysis indicated immune factor-related pathway enrichment in both patient groups. Next, we screened for important genes that are involved in immune cell regulation. Finally, we created a correlation curve to explore the correlation between Riskscore and the expression of these genes.
RESULTS: The prognosis was significantly different between high- and low-risk groups, and the survival rate and survival time of the high-risk group were lower than those of the low-risk group. we found that the pathways related to apoptosis, hypoxia, and immunity were most enriched in the risk groups. we found two common tumor-infiltrating immune cell types (i.e., follicular helper T cells and resting dendritic cells) between the two risk groups and identified 10 genes that regulate these cells. Additionally, we found that these 10 genes are positively associated with the two risk groups.
CONCLUSION: Finally, a risk model of the inflammatory response in gastric cancer was established, and the inflammation-related genes used to construct the model were found to be directly related to immune infiltration. This model can improve the gastric cancer prognosis prediction. Our findings contribute to the development of immunotherapy for the treatment of gastric cancer patients.
Copyright © 2021 Zhao, Liu, Zhang, Wang, Zhang, Wang and Zhang.

Entities:  

Keywords:  gastric cancer; immune cell infiltration; inflammation; risk score; tumor microenvironment

Year:  2021        PMID: 34367971      PMCID: PMC8343517          DOI: 10.3389/fonc.2021.690298

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


Introduction

In 2017, 1.2 million patients were diagnosed with gastric cancer (GC) and there were 865,000 reported deaths worldwide. Between 2007 and 2017, the incidence of gastric cancer increased by 25% (1). In China, gastric cancer is of particular concern as it was the second leading cause of cancer-related deaths in 2015 (2). Although there are many treatments available for gastric cancer, the five-year survival rate for gastric cancer is low. Therefore, it is of urgency to establish a prognostic model that can improve the gastric cancer prognosis prediction. Since the “seed and soil” theory of tumors was published (3), our understanding of the tumor microenvironment has expanded. All of the cells that reside in the tumor microenvironment take part in the formation and development of tumors (4, 5). Studies have shown that chronic inflammation contributes to cancer progression (6). Many tumors develop following chronic inflammation or exhibit chronic inflammation throughout progression (7, 8). The cause of gastric cancer differs among patients owing to differences in genetic and environmental factors, tumor location, histological manifestations, and other molecular features (9). However, chronic Helicobacter pylori infection is the main factor in the development of sporadic stomach cancer, and colonization of gastric epithelium can lead to inflammatory precancerous cascades, including chronic gastritis, atrophic gastritis, and intestinal metaplasia (10). Inflammation creates a microenvironment conducive to cellular transformation and the spread of invasive diseases. In accumulated inflammation, interactions between tumor cells and immune components perpetuate the transformed environment, inducing the transformed tumor cells to acquire mutations and epigenetic changes necessary for cell autonomy (11). In this study, we explored the relationship between inflammation and immunity in gastric cancer to establish an inflammatory risk scoring model. Our findings serve as a basis for further studies focusing on the relationship between inflammation and the immune microenvironment of gastric cancer at the genetic level.

Materials And Methods

Data Collection

The clinical data and the RNA-seq data in this study were obtained from the GSEA website, GEO database and TCGA database. Immunohistochemical images from the Human Protein Atlas (HPA) (https://www.proteinatlas.org) were used to identify the protein expression levels of the corresponding genes.

Establishment of Inflammatory Model

We identified genes that are independently associated with gastric cancer prognosis. The Riskscore of each patient was calculated as the sum of the expression of each gene in the two databases, multiplied by the expression coefficient. Taking the median of the Riskscore as the grouping standard, patients were divided into two groups (high and low) according to the risk value.

Survival Analysis

We used Survival and Survminer packages (The R Foundation for Statistical Computing, Vienna, Austria) in R to analyze patient survival and prognosis. In total, 371 and 433 samples from the two databases were included, respectively. The patient follow-up time in the GEO database was 13 years, whereas that in TGGA database was 10 years. The survival curve was plotted using the Kaplan–Meier method, and the log-rank test was used to assess statistical significance. P <0.05 was a statistically significant standard.

ROC Curve Analysis

We performed the ROC analysis using the R language package (survival, surgeon, and time ROC), to analyze the 1-, 3-, and 5-year survival of patients in the GEO and TCGA databases. The area under the ROC curve was calculated. An area under the curve of >0.5, indicates that the model can accurately predict patient survival. Patient survival in both groups is presented as risk column and a risk curve.

Heatmap Construction

Using the PheatMap software package in R, we created a heat map showing gene expression.

PPI Network Construction

A network of inflammatory genes was constructed using the STRING database. Next, The PPI network was visualized using Cytoscape 3.8.2, and the Cytoscape plug-in, cytoHubba, arranges the network by the number of connections, and selects the first 201 genes with the largest number of adjacent nodes for subsequent analysis.

Cox Regression Analysis

Using the survival package in R, we performed univariate Cox regression analysis using genes associated with inflammation that were closely related to prognosis. Single-factor and multi-factor prognostic analyses were carried out for age, sex, T, N, M, and risk score.

Correlation Between Gene and Inflammation

We screened for important genes that are involved in immune cell regulation. The ggExtra, GGPUBR, and ggplot2 packages in R were used to analyze the correlation between genes and inflammation and the expression difference between inflammation risk groups.

GSEA

By downloading the gene symbols and HALLMARK gene set on the GSEA website, we extracted genes related to inflammation. The entire transcriptome of all tumor samples was used in the GSEA, and genomes with FDR q value <0.06 and nominal P value < 0.05 were considered statistically significant.

Results

Extraction of Inflammation-Related Genes

Previous studies have shown that inflammation and immunity play important roles in the tumor microenvironment. To explore the relationship between inflammation, immunity, and gastric cancer, we downloaded gene ontology (GO) datasets from the Gene Set Enrichment Analysis (GSEA) website to extract genes related to the inflammatory response. Next, we used the STRING PPI (http://stringdb.org/cgi/input.pl) network database and Cytoscape 3.8.2 to construct a protein interaction diagram () of inflammatory response-related genes. The more the number of adjacent nodes in a protein, the redder the color will be, the position is closer to the center, and the protein is more important. Based on this principle, we selected the first 201 core genes that are associated with the largest number of adjacent nodes. We then downloaded the clinical information of gene expression in immune cells and immune cell infiltration profiles in gastric cancer from the TCGA database, to extract the expression of inflammatory genes in this context. Differentially expressed genes were identified by differential analysis, and Cox univariate analysis of these genes was used to screen out the inflammatory response genes most related to prognosis (, P < 0.02). Using this method, we identified 16 genes that were significantly related to prognosis, 15 of which were high-risk genes: THBS1, SELP, SELE, AGT, CCR3, KIT, TGFB1, SERPINE1, HGF, SOCS3, HRH4, C5AR1, FN1, TLR7, and CXCR4, whereas one, IL17RA, is a low-risk gene. Using COX multivariate analysis, from the aforementioned genes, we identified five genes independently affecting prognosis: AGT, SERPINE1, HRH4, TLR7, and IL17RA (). In addition, immunohistochemical images from HPA indicated low levels of HRH4 protein () and high levels of IL-17RA protein () in gastric cancer tissues.
Figure 1

Screening of inflammation-related genes. (A) PPI network (interaction confidence values > 0.4). (B) Univariate Cox regression analysis (P < 0.05). (C) From the genes related to the prognosis of gastric cancer, the genes that are independently related to the patient’s prognosis were screened out and used to construct a multi-factor prognostic model of inflammation.

Figure 2

Difference in protein expression of inflammation-related genes. (A, B) HRH4 expression was down regulated and (C, D) IL-17RA expression was upregulated among gastric cancer samples in immunohistochemical images.

Screening of inflammation-related genes. (A) PPI network (interaction confidence values > 0.4). (B) Univariate Cox regression analysis (P < 0.05). (C) From the genes related to the prognosis of gastric cancer, the genes that are independently related to the patient’s prognosis were screened out and used to construct a multi-factor prognostic model of inflammation. Difference in protein expression of inflammation-related genes. (A, B) HRH4 expression was down regulated and (C, D) IL-17RA expression was upregulated among gastric cancer samples in immunohistochemical images.

Establishment of the Prognostic Model

We examined the relationship between the prognostic models and patient survival. To obtain the risk score of each patient, we multiplied the coefficients of five genes (AGT, SERPINE1, HRH4, TLR7, and IL17RA) from the GEO and TCGA databases by the corresponding expression. The gene coefficients of SERPINE1, HRH4, AGT, TLR7, and IL17RA were 0.2782, 1.5074, 0.1174, 0.3074, and -1.0345, respectively. The patients in TCGA and GEO databases were divided into two groups according to risk (high and low), and the grouping criterion was the median of the Riskscore. The subsequent survival analysis revealed that the survival status between the two groups is significantly different (, P < 0.05). The accuracy of the model for assessing survival conditions was verified using an receiver operating characteristic (ROC) curve, and the areas under the curves for 1-, 3-, and 5-year survival gradually increased in the TCGA database (). In the GEO database, the area under the ROC curve was >0.05, and the difference was not significant (), indicating that the predictive value of this model for prognosis requires improvement. A risk histogram was used to display the patient survival status in the two databases (). The low-risk group has a high survival rate. High- and low-risk patients can be distinguished using this model. Additionally, gene interactions in the model were analyzed (). By drawing the risk curve, we explored the relationship between the survival status and the risk of patients. show the risk value of patients in the two groups in the TCGA and GEO databases (). Patients in the low-risk group had a longer survival and a lower risk of death than those in the high-risk group (). Finally, we used a heat map to show the expression of the genes of the model in the two risk groups ().
Figure 3

Relationship between the inflammation risk score model and patient prognosis. (A, B) Kaplan–Meier survival curves for patients with gastric cancer in TCGA and GEO databases stratified by high- and low-risk scores. We used the log-rank test to compare the median survival time of patients in the high- and low-risk groups (P < 0.001 and P = 0.030, respectively). (C, D) Analysis of the prognostic accuracy of the model through the receiver operating characteristic curve. In TCGA cohort, the areas under the 1-, 3-, and 5-year survival curves gradually increased, whereas in the GEO cohort, no significant change was observed.

Figure 4

Prediction of patient risk and the expression levels of the genes included in the model in the two risk groups in TCGA and GEO databases. The patient data used were obtained from TCGA and GEO databases. (A, B) Patient survival. (C, D) Correlations between the risk model genes. Positive correlation is represented by red, and negative correlation is represented by green. (E, F) Patient risk scores. (G, H) Patient survival rates in the two risk groups. (I, J) Heat maps of gene expression levels in the risk models of the two risk groups.

Relationship between the inflammation risk score model and patient prognosis. (A, B) Kaplan–Meier survival curves for patients with gastric cancer in TCGA and GEO databases stratified by high- and low-risk scores. We used the log-rank test to compare the median survival time of patients in the high- and low-risk groups (P < 0.001 and P = 0.030, respectively). (C, D) Analysis of the prognostic accuracy of the model through the receiver operating characteristic curve. In TCGA cohort, the areas under the 1-, 3-, and 5-year survival curves gradually increased, whereas in the GEO cohort, no significant change was observed. Prediction of patient risk and the expression levels of the genes included in the model in the two risk groups in TCGA and GEO databases. The patient data used were obtained from TCGA and GEO databases. (A, B) Patient survival. (C, D) Correlations between the risk model genes. Positive correlation is represented by red, and negative correlation is represented by green. (E, F) Patient risk scores. (G, H) Patient survival rates in the two risk groups. (I, J) Heat maps of gene expression levels in the risk models of the two risk groups.

Effects of Different Clinical Traits and Riskscore on Gastric Cancer Prognosis

We analyzed whether Riskscore and other clinical traits were independent prognostic factors. We explored the effects of Riskscore and different clinical traits [age, gender, and tumor–node–metastasis (TNM)] on the prognosis of patients in the two databases. Firstly, Cox univariate analysis was used to analyze the effects of clinical traits and Riskscore on the survival of patients in TCGA and GEO databases (). High-risk factors other than gender, such as age, T, N, and Riskscore, can influence prognosis. We also found that Riskscore influences patient prognosis: according to the results of multivariate analysis, Riskscore, age, and N are independent prognostic factors (). The expression of inflammatory response genes between different T stages is shown in (), and the expression of inflammatory response-related genes used to construct the prognostic model in TCGA and GEO databases at different T stages is shown in and . The differential expression of TLR7 and SERPINE1 at different T stages in TCGA and GEO databases was the most significant (P < 0.05).
Figure 5

Relationships between risk models and clinical factors. Patient data were obtained from the TCGA and GEO databases. (A, B) Single-factor prognostic analysis including grade, gender, age, tumor– node–metastasis (TNM) stage, and the risk scores of patients. (C, D) Multi-factor prognostic analysis included the TNM stage, age, and risk scores. (E, F) The expression levels of various genes in the inflammatory model at different T stages and (G, H) the corresponding heatmaps.

Relationships between risk models and clinical factors. Patient data were obtained from the TCGA and GEO databases. (A, B) Single-factor prognostic analysis including grade, gender, age, tumor– node–metastasis (TNM) stage, and the risk scores of patients. (C, D) Multi-factor prognostic analysis included the TNM stage, age, and risk scores. (E, F) The expression levels of various genes in the inflammatory model at different T stages and (G, H) the corresponding heatmaps.

Pathway Enrichment Analysis

We found that the high-risk groups in the two databases displayed enrichment of immune, hypoxia, and apoptotic pathways (), including IL-2STA T5 signaling, TNFA signaling, and IL-6-STA T3 signaling. Meanwhile, the low-risk groups were enriched with PI3K-Akt-mTOR signaling, oxidative phosphorylation, reactive oxygen species, peroxisome activity, and p53 signaling ().
Figure 6

Inflammatory pathway enrichment analysis and infiltration of inflammation-related immune cells. (A–D) Enriched gene sets according to high- and low-risk scores in TCGA and GEO databases. Each line represents a specific gene set, with upregulated genes on the left side approaching the origin of the coordinates and downregulated genes on the right side of the x axis. Gene sets (nominal (NOM) P < 0.05 and false discovery rate (FDR) q < 0.06). A selection of leading enriched gene sets is shown. (E, F) Heatmap showing immune cell infiltration between high-and low-risk groups in the two databases.

Inflammatory pathway enrichment analysis and infiltration of inflammation-related immune cells. (A–D) Enriched gene sets according to high- and low-risk scores in TCGA and GEO databases. Each line represents a specific gene set, with upregulated genes on the left side approaching the origin of the coordinates and downregulated genes on the right side of the x axis. Gene sets (nominal (NOM) P < 0.05 and false discovery rate (FDR) q < 0.06). A selection of leading enriched gene sets is shown. (E, F) Heatmap showing immune cell infiltration between high-and low-risk groups in the two databases.

Immune Cell Infiltration

Pathway enrichment analysis indicated immune factor-related pathway enrichment in both patient groups. Thus, we further clarified the infiltration of immune cells in each risk group in these two databases. show the infiltration of immune cells in the two risk groups in the GEO and TCGA databases, respectively (). In TCGA database, there were eight types of immune cells with significantly different infiltration in the two risk groups (, P < 0.05). In the GEO database, we found that seven types of immune cell infiltration are significantly different in the two risk groups (, P < 0.05).
Figure 7

Differentially infiltrating immune cells of inflammation-associated risk groups. (A, B) Immune cells whose infiltration is related with inflammation risk score in the two databases (P < 0.05). (C, D) Heatmaps show the expression levels of genes regulating activated follicular helper T cells and resting dendritic cells in the two risk groups (*P < 0.05; **P < 0.01; ***P < 0.001).

Differentially infiltrating immune cells of inflammation-associated risk groups. (A, B) Immune cells whose infiltration is related with inflammation risk score in the two databases (P < 0.05). (C, D) Heatmaps show the expression levels of genes regulating activated follicular helper T cells and resting dendritic cells in the two risk groups (*P < 0.05; **P < 0.01; ***P < 0.001). Moreover, we found differences in the infiltration of follicular helper T cells and resting dendritic cells in each group in the two databases. We downloaded immune-related genes from the Tracking Tumor Immunophenotype website, and the genes regulating T cell follicular helper and dendritic cell resting were selected. The heat map shows the expression of these genes in the two risk groups of the two databases (). We found that the expression of 10 genes, (EZH2, EDNRB, CCL21, CCL19, CCL2, CCL5, CCR7, ITGB2, CXCL9, and CXCL) was significantly different between high- and low-risk groups in the two databases (P < 0.05). Next, we created a correlation curve to explore the correlation between Riskscore and the expression of these genes and found that all the 10 genes were differentially expressed in the two risk groups of TCGA and GEO databases (, ). EZH2 was negatively correlated with Riskscore, whereas the other genes were positively correlated. Therefore, we constructed a prognostic model of inflammation-related genes in gastric cancer that could improve the gastric cancer prognosis prediction. Moreover, we found a relationship between the prognostic model and immune cell infiltration.
Figure 8

Relationships between inflammatory Riskscore and genes regulating immune cell behavior. Scatter plots show the correlations between immune cell regulation and the expression of 10 genes from the two databases. We found significant differences in the expression levels among different inflammation risk groups (P < 0.05). The blue line in each plot is a fitted linear model indicating the relationship between gene expression and the risk of inflammation. The box plots show the differences of gene expression between risk groups (P < 0.05).

Figure 9

Relationships between inflammatory Riskscore and genes regulating immune cell behavior. Scatter plots show the correlations between immune cell regulation and the expression of 10 genes from the two databases. We found significant differences in the expression levels among different inflammation risk groups (P < 0.05). The blue line in each plot is a fitted linear model indicating the relationship between gene expression and the risk of inflammation. The box plots show the differences of gene expression between risk groups (P < 0.05).

Relationships between inflammatory Riskscore and genes regulating immune cell behavior. Scatter plots show the correlations between immune cell regulation and the expression of 10 genes from the two databases. We found significant differences in the expression levels among different inflammation risk groups (P < 0.05). The blue line in each plot is a fitted linear model indicating the relationship between gene expression and the risk of inflammation. The box plots show the differences of gene expression between risk groups (P < 0.05). Relationships between inflammatory Riskscore and genes regulating immune cell behavior. Scatter plots show the correlations between immune cell regulation and the expression of 10 genes from the two databases. We found significant differences in the expression levels among different inflammation risk groups (P < 0.05). The blue line in each plot is a fitted linear model indicating the relationship between gene expression and the risk of inflammation. The box plots show the differences of gene expression between risk groups (P < 0.05).

Discussion

Inflammation and stomach cancer are closely related. Inflammation plays an important role in malignant transformation (12), in which inflammation-related genes are the core of inflammation, as they act on the corresponding channel or regulating immune cells. In normal conditions, NF-κB signaling affects the regulation of inflammation and immune response. Some studies have found that the overactivation of the NF-κB pathway is a hallmark of inflammation-related cancers (13). Helicobacter pylori infection is one of the main causes of chronic inflammation of the stomach, leading to the overexpression of Aurora kinase A (AURKA), which activates NF-κB in the gastric mucosa (14). Inflammatory factors produced by infiltrating immune cells are sustained, thereby accelerating the initiation of tumor formation (15). In this study, we screened genes related to inflammation and identified core genes to further verify the prognostic value of these genes. Except that SELE and KIT are not being studied in depth right now, we found several genes that were related to the prognosis and survival of gastric cancer patients. Among them, AGT, SERPINE1, HRH4, TLR7, and IL17RA can independently affect prognosis. Previous studies have shown that increased SERPINE1 expression can prevent apoptosis (16). In line with this, as expression of SERPINE1 in gastric cancer tissues is significantly increased, it is a likely contributing factor to the poor prognosis of patients with stomach cancer (17). In our study, univariate and multivariate Cox analyses showed that SERPINE1 was a high-risk factor, which may be due to its high expression in gastric cancer patients. Previous studies have found that TLR7 expression is reduced in stomach cancer. Increased TLR7 expression promotes the production of proinflammatory cytokines and inhibits the growth of gastric cancer cells (18). We speculate that TLR7 may be a high-risk factor due to its low expression in gastric cancer. Some studies show that deletion of HRH4 gene is present in gastric cancer cases and is closely correlated with attenuated gene expression. Down-regulation of HRH4 in gastric carcinomas plays a role in histamine-mediated growth control of gastric cancer cells (19). IL17A exerts its tumor-promoting activity through its type A receptor (IL-17RA), which is expressed in various cell types in the tumor microenvironment, including hematopoietic cells, fibroblasts, and epithelial cells (20). In addition, immunohistochemical images from HPA indicated high levels of IL-17RA protein and low levels of HRH4 protein in gastric cancer tissues. These inflammation-related genes are closely related to tumors to a large extent, which is conducive to the establishment of a subsequent inflammation model. With an increased understanding of inflammation, scientists have recently reported on the relationship between inflammation and tumors (12, 21). In this study, we used the product sum of the expression levels and the coefficients of AGT, SERPINE1, HRH4, TLR7, and IL17RA as the risk score to evaluate patient prognosis in the TCGA and GEO databases. Patient prognosis between the two Riskscore groups was significantly different, and the patient survival in the low Riskscore group was significantly prolonged. In addition, we analyzed the effects of our Riskscore, age, sex, and T, M, and N staging on patient survival and prognosis. Riskscore has a corresponding impact on patient prognosis and can predict the prognosis of patients independent of other clinical traits. Through pathway enrichment analysis, we found that the pathways related to apoptosis, hypoxia, and immunity were most enriched. There is often a hypoxic environment and apoptosis in tumor tissues, producing a large number of inflammatory factors. These factors can chemoattract macrophages and induce their polarization. Polarized macrophages can further produce inflammatory factors (22). Therefore, there is a close relationship between inflammation and the immune response. Several studies have previously found that inflammatory mediators can promote tumor progression and metastasis (23) and that the innate and adaptive immune systems can protect the host from tumor invasion through immune-monitoring mechanisms (24). Moreover, the increased sensitivity of immunodeficient mice to carcinogenesis and spontaneous tumors suggests that both innate and adaptive immunity can control tumor development (24–26). In addition, we identified eight types of immune cells from TCGA database with differential infiltrations between the two patient groups. From the GEO database, in the two risk groups, the infiltration of seven immune cells was significantly different. Additionally, the infiltration of follicular helper T cells and resting dendritic cells in the two groups of the two databases was different. We then screened the genes that regulate these two cells and found that the expression of EZH2, EDNRB, CCL21, CCL19, CCL2, CCL5, CCR7, ITGB2, CXCL9, and CXCL10 were different between the two risk groups. Our study also found that the expression of these genes was significantly associated with inflammatory risk scores. Six of these ten genes are chemokines, which can chemoattract immune cells and effect the development of tumors. CCL2 and CCL5 are closely related to prostate tumor metastasis and tumor resistance (27, 28). EZH2 has the same characteristics as oncogenes; its overexpression in vitro is closely related to cell proliferation, colony formation, and benign cell invasion (29–31), and it induces xenograft tumor growth in vivo (32). Similarly, downregulation of EZH2 expression in cancer cells can lead to growth arrest (31, 32), reduced tumor growth (33), and reduced metastasis (34). According to Kattan nomogram calculations, the CpG island hypermethylation of EDNRB is negatively correlated with the probability of survival without prostate-specific antigen (35). Meanwhile, a higher expression of CCL21 in stomach cancer tissues is closely related to lymph node metastasis, high incidence of tumor metastasis, and depth of gastric wall invasion (36). The proliferation, migration, and invasion of stomach cancer cells are inhibited by CCL19 via the CCL19/CCR7/AIM2 pathway (37). Compared to healthy volunteers, the serum level of CCL5 of gastric cancer patients was also increased, and increased exogenous CCL5 level enhanced the migration ability of AGS cells across the transwell membrane (38). A meta-analysis study suggested that high CCR7 expression may lead to poor survival and prognosis in patients with gastric cancer (39). Clinical studies on gastric cancer samples showed that CXCL9 was positively correlated with better patients prognosis (40). Studies have also found that the overexpression of CCL5 and CXCL9 in solid tumors is associated with CD8+ T cell infiltration. In tumor tissues, T cell infiltration requires CCL5 derived from tumor cells and is amplified by CXCL9 secreted by myeloid cells induced by interferon-g (41). The invasion and migration of gastric cancer cells can be promoted by MMP-2 and MMP-9, which are upregulated by the CXCL10/CXCR3 axis (42). At present, the relationship between ITGB2 and gastric cancer has not been thoroughly studied. However, this study only included bioinformatics analysis. It only proves that the Riskscore model we established is related to the prognosis of gastric cancer, and the specific mechanism of the influence of inflammation-related genes on the prognosis has not been explored; thus, prospective studies, like some basic research and clinical studies should be carried out to determine the causal relationship between this model and the prognosis of gastric cancer and explore the specific mechanisms of the interaction between the genes we have identified and gastric cancer. In conclusion, we identified inflammation-related genes related to the prognosis of gastric cancer. Our findings provide new insights on the relationship between inflammation and immunity in gastric cancer and contribute to the development of immunotherapy for the treatment of gastric cancer patients.

Data Availability Statement

Publicly available datasets were analyzed in this study. This data can be found here: The Cancer Genome Atlas (TCGA) and GEO, GSE84437.

Author Contributions

The data analysis and original writing of the draft were conducted by WZ and ML. SW and NZ came up with the design and critical revision of the manuscript. The original writing of the draft and its editing were by MZ, YW, and YZ. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by Finance Department of Jilin (2018SCZWSZX-039) and Finance Department of Jilin (JLSWSRCZX2020-083) and China Postdoctoral Science Foundation (2020M670034ZX).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  40 in total

Review 1.  Accessories to the crime: functions of cells recruited to the tumor microenvironment.

Authors:  Douglas Hanahan; Lisa M Coussens
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 2.  Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma.

Authors:  Patrick Tan; Khay-Guan Yeoh
Journal:  Gastroenterology       Date:  2015-06-12       Impact factor: 22.682

3.  CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis.

Authors:  Tsann-Long Hwang; Li-Yu Lee; Chee-Chan Wang; Ying Liang; Shu-Fang Huang; Chi-Ming Wu
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

Review 4.  Chronic inflammation and the development of malignancy in the GI tract.

Authors:  Stefan Fichtner-Feigl; Rebecca Kesselring; Warren Strober
Journal:  Trends Immunol       Date:  2015-07-18       Impact factor: 16.687

5.  Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells.

Authors:  Jiong Jiang; Lei Dong; Bin Qin; Haitao Shi; Xiaoyan Guo; Yan Wang
Journal:  Oncol Lett       Date:  2016-05-24       Impact factor: 2.967

6.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Degu Abate; Naghmeh Abbasi; Hedayat Abbastabar; Foad Abd-Allah; Omar Abdel-Rahman; Ahmed Abdelalim; Amir Abdoli; Ibrahim Abdollahpour; Abdishakur S M Abdulle; Nebiyu Dereje Abebe; Haftom Niguse Abraha; Laith Jamal Abu-Raddad; Ahmed Abualhasan; Isaac Akinkunmi Adedeji; Shailesh M Advani; Mohsen Afarideh; Mahdi Afshari; Mohammad Aghaali; Dominic Agius; Sutapa Agrawal; Ayat Ahmadi; Elham Ahmadian; Ehsan Ahmadpour; Muktar Beshir Ahmed; Mohammad Esmaeil Akbari; Tomi Akinyemiju; Ziyad Al-Aly; Assim M AlAbdulKader; Fares Alahdab; Tahiya Alam; Genet Melak Alamene; Birhan Tamene T Alemnew; Kefyalew Addis Alene; Cyrus Alinia; Vahid Alipour; Syed Mohamed Aljunid; Fatemeh Allah Bakeshei; Majid Abdulrahman Hamad Almadi; Amir Almasi-Hashiani; Ubai Alsharif; Shirina Alsowaidi; Nelson Alvis-Guzman; Erfan Amini; Saeed Amini; Yaw Ampem Amoako; Zohreh Anbari; Nahla Hamed Anber; Catalina Liliana Andrei; Mina Anjomshoa; Fereshteh Ansari; Ansariadi Ansariadi; Seth Christopher Yaw Appiah; Morteza Arab-Zozani; Jalal Arabloo; Zohreh Arefi; Olatunde Aremu; Habtamu Abera Areri; Al Artaman; Hamid Asayesh; Ephrem Tsegay Asfaw; Alebachew Fasil Ashagre; Reza Assadi; Bahar Ataeinia; Hagos Tasew Atalay; Zerihun Ataro; Suleman Atique; Marcel Ausloos; Leticia Avila-Burgos; Euripide F G A Avokpaho; Ashish Awasthi; Nefsu Awoke; Beatriz Paulina Ayala Quintanilla; Martin Amogre Ayanore; Henok Tadesse Ayele; Ebrahim Babaee; Umar Bacha; Alaa Badawi; Mojtaba Bagherzadeh; Eleni Bagli; Senthilkumar Balakrishnan; Abbas Balouchi; Till Winfried Bärnighausen; Robert J Battista; Masoud Behzadifar; Meysam Behzadifar; Bayu Begashaw Bekele; Yared Belete Belay; Yaschilal Muche Belayneh; Kathleen Kim Sachiko Berfield; Adugnaw Berhane; Eduardo Bernabe; Mircea Beuran; Nickhill Bhakta; Krittika Bhattacharyya; Belete Biadgo; Ali Bijani; Muhammad Shahdaat Bin Sayeed; Charles Birungi; Catherine Bisignano; Helen Bitew; Tone Bjørge; Archie Bleyer; Kassawmar Angaw Bogale; Hunduma Amensisa Bojia; Antonio M Borzì; Cristina Bosetti; Ibrahim R Bou-Orm; Hermann Brenner; Jerry D Brewer; Andrey Nikolaevich Briko; Nikolay Ivanovich Briko; Maria Teresa Bustamante-Teixeira; Zahid A Butt; Giulia Carreras; Juan J Carrero; Félix Carvalho; Clara Castro; Franz Castro; Ferrán Catalá-López; Ester Cerin; Yazan Chaiah; Wagaye Fentahun Chanie; Vijay Kumar Chattu; Pankaj Chaturvedi; Neelima Singh Chauhan; Mohammad Chehrazi; Peggy Pei-Chia Chiang; Tesfaye Yitna Chichiabellu; Onyema Greg Chido-Amajuoyi; Odgerel Chimed-Ochir; Jee-Young J Choi; Devasahayam J Christopher; Dinh-Toi Chu; Maria-Magdalena Constantin; Vera M Costa; Emanuele Crocetti; Christopher Stephen Crowe; Maria Paula Curado; Saad M A Dahlawi; Giovanni Damiani; Amira Hamed Darwish; Ahmad Daryani; José das Neves; Feleke Mekonnen Demeke; Asmamaw Bizuneh Demis; Birhanu Wondimeneh Demissie; Gebre Teklemariam Demoz; Edgar Denova-Gutiérrez; Afshin Derakhshani; Kalkidan Solomon Deribe; Rupak Desai; Beruk Berhanu Desalegn; Melaku Desta; Subhojit Dey; Samath Dhamminda Dharmaratne; Meghnath Dhimal; Daniel Diaz; Mesfin Tadese Tadese Dinberu; Shirin Djalalinia; David Teye Doku; Thomas M Drake; Manisha Dubey; Eleonora Dubljanin; Eyasu Ejeta Duken; Hedyeh Ebrahimi; Andem Effiong; Aziz Eftekhari; Iman El Sayed; Maysaa El Sayed Zaki; Shaimaa I El-Jaafary; Ziad El-Khatib; Demelash Abewa Elemineh; Hajer Elkout; Richard G Ellenbogen; Aisha Elsharkawy; Mohammad Hassan Emamian; Daniel Adane Endalew; Aman Yesuf Endries; Babak Eshrati; Ibtihal Fadhil; Vahid Fallah Omrani; Mahbobeh Faramarzi; Mahdieh Abbasalizad Farhangi; Andrea Farioli; Farshad Farzadfar; Netsanet Fentahun; Eduarda Fernandes; Garumma Tolu Feyissa; Irina Filip; Florian Fischer; James L Fisher; Lisa M Force; Masoud Foroutan; Marisa Freitas; Takeshi Fukumoto; Neal D Futran; Silvano Gallus; Fortune Gbetoho Gankpe; Reta Tsegaye Gayesa; Tsegaye Tewelde Gebrehiwot; Gebreamlak Gebremedhn Gebremeskel; Getnet Azeze Gedefaw; Belayneh K Gelaw; Birhanu Geta; Sefonias Getachew; Kebede Embaye Gezae; Mansour Ghafourifard; Alireza Ghajar; Ahmad Ghashghaee; Asadollah Gholamian; Paramjit Singh Gill; Themba T G Ginindza; Alem Girmay; Muluken Gizaw; Ricardo Santiago Gomez; Sameer Vali Gopalani; Giuseppe Gorini; Bárbara Niegia Garcia Goulart; Ayman Grada; Maximiliano Ribeiro Guerra; Andre Luiz Sena Guimaraes; Prakash C Gupta; Rahul Gupta; Kishor Hadkhale; Arvin Haj-Mirzaian; Arya Haj-Mirzaian; Randah R Hamadeh; Samer Hamidi; Lolemo Kelbiso Hanfore; Josep Maria Haro; Milad Hasankhani; Amir Hasanzadeh; Hamid Yimam Hassen; Roderick J Hay; Simon I Hay; Andualem Henok; Nathaniel J Henry; Claudiu Herteliu; Hagos D Hidru; Chi Linh Hoang; Michael K Hole; Praveen Hoogar; Nobuyuki Horita; H Dean Hosgood; Mostafa Hosseini; Mehdi Hosseinzadeh; Mihaela Hostiuc; Sorin Hostiuc; Mowafa Househ; Mohammedaman Mama Hussen; Bogdan Ileanu; Milena D Ilic; Kaire Innos; Seyed Sina Naghibi Irvani; Kufre Robert Iseh; Sheikh Mohammed Shariful Islam; Farhad Islami; Nader Jafari Balalami; Morteza Jafarinia; Leila Jahangiry; Mohammad Ali Jahani; Nader Jahanmehr; Mihajlo Jakovljevic; Spencer L James; Mehdi Javanbakht; Sudha Jayaraman; Sun Ha Jee; Ensiyeh Jenabi; Ravi Prakash Jha; Jost B Jonas; Jitendra Jonnagaddala; Tamas Joo; Suresh Banayya Jungari; Mikk Jürisson; Ali Kabir; Farin Kamangar; André Karch; Narges Karimi; Ansar Karimian; Amir Kasaeian; Gebremicheal Gebreslassie Kasahun; Belete Kassa; Tesfaye Dessale Kassa; Mesfin Wudu Kassaw; Anil Kaul; Peter Njenga Keiyoro; Abraham Getachew Kelbore; Amene Abebe Kerbo; Yousef Saleh Khader; Maryam Khalilarjmandi; Ejaz Ahmad Khan; Gulfaraz Khan; Young-Ho Khang; Khaled Khatab; Amir Khater; Maryam Khayamzadeh; Maryam Khazaee-Pool; Salman Khazaei; Abdullah T Khoja; Mohammad Hossein Khosravi; Jagdish Khubchandani; Neda Kianipour; Daniel Kim; Yun Jin Kim; Adnan Kisa; Sezer Kisa; Katarzyna Kissimova-Skarbek; Hamidreza Komaki; Ai Koyanagi; Kristopher J Krohn; Burcu Kucuk Bicer; Nuworza Kugbey; Vivek Kumar; Desmond Kuupiel; Carlo La Vecchia; Deepesh P Lad; Eyasu Alem Lake; Ayenew Molla Lakew; Dharmesh Kumar Lal; Faris Hasan Lami; Qing Lan; Savita Lasrado; Paolo Lauriola; Jeffrey V Lazarus; James Leigh; Cheru Tesema Leshargie; Yu Liao; Miteku Andualem Limenih; Stefan Listl; Alan D Lopez; Platon D Lopukhov; Raimundas Lunevicius; Mohammed Madadin; Sameh Magdeldin; Hassan Magdy Abd El Razek; Azeem Majeed; Afshin Maleki; Reza Malekzadeh; Ali Manafi; Navid Manafi; Wondimu Ayele Manamo; Morteza Mansourian; Mohammad Ali Mansournia; Lorenzo Giovanni Mantovani; Saman Maroufizadeh; Santi Martini S Martini; Tivani Phosa Mashamba-Thompson; Benjamin Ballard Massenburg; Motswadi Titus Maswabi; Manu Raj Mathur; Colm McAlinden; Martin McKee; Hailemariam Abiy Alemu Meheretu; Ravi Mehrotra; Varshil Mehta; Toni Meier; Yohannes A Melaku; Gebrekiros Gebremichael Meles; Hagazi Gebre Meles; Addisu Melese; Mulugeta Melku; Peter T N Memiah; Walter Mendoza; Ritesh G Menezes; Shahin Merat; Tuomo J Meretoja; Tomislav Mestrovic; Bartosz Miazgowski; Tomasz Miazgowski; Kebadnew Mulatu M Mihretie; Ted R Miller; Edward J Mills; Seyed Mostafa Mir; Hamed Mirzaei; Hamid Reza Mirzaei; Rashmi Mishra; Babak Moazen; Dara K Mohammad; Karzan Abdulmuhsin Mohammad; Yousef Mohammad; Aso Mohammad Darwesh; Abolfazl Mohammadbeigi; Hiwa Mohammadi; Moslem Mohammadi; Mahdi Mohammadian; Abdollah Mohammadian-Hafshejani; Milad Mohammadoo-Khorasani; Reza Mohammadpourhodki; Ammas Siraj Mohammed; Jemal Abdu Mohammed; Shafiu Mohammed; Farnam Mohebi; Ali H Mokdad; Lorenzo Monasta; Yoshan Moodley; Mahmood Moosazadeh; Maryam Moossavi; Ghobad Moradi; Mohammad Moradi-Joo; Maziar Moradi-Lakeh; Farhad Moradpour; Lidia Morawska; Joana Morgado-da-Costa; Naho Morisaki; Shane Douglas Morrison; Abbas Mosapour; Seyyed Meysam Mousavi; Achenef Asmamaw Muche; Oumer Sada S Muhammed; Jonah Musa; Ashraf F Nabhan; Mehdi Naderi; Ahamarshan Jayaraman Nagarajan; Gabriele Nagel; Azin Nahvijou; Gurudatta Naik; Farid Najafi; Luigi Naldi; Hae Sung Nam; Naser Nasiri; Javad Nazari; Ionut Negoi; Subas Neupane; Polly A Newcomb; Haruna Asura Nggada; Josephine W Ngunjiri; Cuong Tat Nguyen; Leila Nikniaz; Dina Nur Anggraini Ningrum; Yirga Legesse Nirayo; Molly R Nixon; Chukwudi A Nnaji; Marzieh Nojomi; Shirin Nosratnejad; Malihe Nourollahpour Shiadeh; Mohammed Suleiman Obsa; Richard Ofori-Asenso; Felix Akpojene Ogbo; In-Hwan Oh; Andrew T Olagunju; Tinuke O Olagunju; Mojisola Morenike Oluwasanu; Abidemi E Omonisi; Obinna E Onwujekwe; Anu Mary Oommen; Eyal Oren; Doris D V Ortega-Altamirano; Erika Ota; Stanislav S Otstavnov; Mayowa Ojo Owolabi; Mahesh P A; Jagadish Rao Padubidri; Smita Pakhale; Amir H Pakpour; Adrian Pana; Eun-Kee Park; Hadi Parsian; Tahereh Pashaei; Shanti Patel; Snehal T Patil; Alyssa Pennini; David M Pereira; Cristiano Piccinelli; Julian David Pillay; Majid Pirestani; Farhad Pishgar; Maarten J Postma; Hadi Pourjafar; Farshad Pourmalek; Akram Pourshams; Swayam Prakash; Narayan Prasad; Mostafa Qorbani; Mohammad Rabiee; Navid Rabiee; Amir Radfar; Alireza Rafiei; Fakher Rahim; Mahdi Rahimi; Muhammad Aziz Rahman; Fatemeh Rajati; Saleem M Rana; Samira Raoofi; Goura Kishor Rath; David Laith Rawaf; Salman Rawaf; Robert C Reiner; Andre M N Renzaho; Nima Rezaei; Aziz Rezapour; Ana Isabel Ribeiro; Daniela Ribeiro; Luca Ronfani; Elias Merdassa Roro; Gholamreza Roshandel; Ali Rostami; Ragy Safwat Saad; Parisa Sabbagh; Siamak Sabour; Basema Saddik; Saeid Safiri; Amirhossein Sahebkar; Mohammad Reza Salahshoor; Farkhonde Salehi; Hosni Salem; Marwa Rashad Salem; Hamideh Salimzadeh; Joshua A Salomon; Abdallah M Samy; Juan Sanabria; Milena M Santric Milicevic; Benn Sartorius; Arash Sarveazad; Brijesh Sathian; Maheswar Satpathy; Miloje Savic; Monika Sawhney; Mehdi Sayyah; Ione J C Schneider; Ben Schöttker; Mario Sekerija; Sadaf G Sepanlou; Masood Sepehrimanesh; Seyedmojtaba Seyedmousavi; Faramarz Shaahmadi; Hosein Shabaninejad; Mohammad Shahbaz; Masood Ali Shaikh; Amir Shamshirian; Morteza Shamsizadeh; Heidar Sharafi; Zeinab Sharafi; Mehdi Sharif; Ali Sharifi; Hamid Sharifi; Rajesh Sharma; Aziz Sheikh; Reza Shirkoohi; Sharvari Rahul Shukla; Si Si; Soraya Siabani; Diego Augusto Santos Silva; Dayane Gabriele Alves Silveira; Ambrish Singh; Jasvinder A Singh; Solomon Sisay; Freddy Sitas; Eugène Sobngwi; Moslem Soofi; Joan B Soriano; Vasiliki Stathopoulou; Mu'awiyyah Babale Sufiyan; Rafael Tabarés-Seisdedos; Takahiro Tabuchi; Ken Takahashi; Omid Reza Tamtaji; Mohammed Rasoul Tarawneh; Segen Gebremeskel Tassew; Parvaneh Taymoori; Arash Tehrani-Banihashemi; Mohamad-Hani Temsah; Omar Temsah; Berhe Etsay Tesfay; Fisaha Haile Tesfay; Manaye Yihune Teshale; Gizachew Assefa Tessema; Subash Thapa; Kenean Getaneh Tlaye; Roman Topor-Madry; Marcos Roberto Tovani-Palone; Eugenio Traini; Bach Xuan Tran; Khanh Bao Tran; Afewerki Gebremeskel Tsadik; Irfan Ullah; Olalekan A Uthman; Marco Vacante; Maryam Vaezi; Patricia Varona Pérez; Yousef Veisani; Simone Vidale; Francesco S Violante; Vasily Vlassov; Stein Emil Vollset; Theo Vos; Kia Vosoughi; Giang Thu Vu; Isidora S Vujcic; Henry Wabinga; Tesfahun Mulatu Wachamo; Fasil Shiferaw Wagnew; Yasir Waheed; Fitsum Weldegebreal; Girmay Teklay Weldesamuel; Tissa Wijeratne; Dawit Zewdu Wondafrash; Tewodros Eshete Wonde; Adam Belay Wondmieneh; Hailemariam Mekonnen Workie; Rajaram Yadav; Abbas Yadegar; Ali Yadollahpour; Mehdi Yaseri; Vahid Yazdi-Feyzabadi; Alex Yeshaneh; Mohammed Ahmed Yimam; Ebrahim M Yimer; Engida Yisma; Naohiro Yonemoto; Mustafa Z Younis; Bahman Yousefi; Mahmoud Yousefifard; Chuanhua Yu; Erfan Zabeh; Vesna Zadnik; Telma Zahirian Moghadam; Zoubida Zaidi; Mohammad Zamani; Hamed Zandian; Alireza Zangeneh; Leila Zaki; Kazem Zendehdel; Zerihun Menlkalew Zenebe; Taye Abuhay Zewale; Arash Ziapour; Sanjay Zodpey; Christopher J L Murray
Journal:  JAMA Oncol       Date:  2019-12-01       Impact factor: 31.777

View more
  2 in total

1.  Identification and Validation of an m6A Modification of JAK-STAT Signaling Pathway-Related Prognostic Prediction Model in Gastric Cancer.

Authors:  Fei Jiang; Xiaowei Chen; Yan Shen; Xiaobing Shen
Journal:  Front Genet       Date:  2022-07-19       Impact factor: 4.772

2.  Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma.

Authors:  Cheng Zeng; Yu Liu; Rong He; Xiaohuan Lu; Yuyang Dai; Guoping Qi; Jingsong Liu; Jianzhong Deng; Wenbin Lu; Jianhua Jin; Qian Liu
Journal:  Front Genet       Date:  2022-08-25       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.